 |
|
|
| |
HIV Glasgow 2022
23-26 October
Virtual Meeting |
| |
| |
- The Glasgow Manifesto International Coalition
of Older People with HIV (iCOPe HIV) - (10/26/22)
- Comparison of HIV Incidence as Determined by Different Recency Assays in Ugandan Women - (12/08/22)
-
Efficacy and Safety of Switching to Dolutegravir
Plus Rilpivirine in Virologically Suppressed Older PLWH:
Pooled Week 148 Results From SWORD-1 and SWORD-2 - (11/17/22)
- Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Black and Asian Participants From TANGO and SALSA: Pooled 48-Week Data Analyzed by Race - (11/17/22)
-
Effectiveness of Dolutegravir + Lamivudine in Real-world Studies in People With HIV-1 With M184V/I Mutations: A Systematic Review and Meta-analysis - (11/17/22)
-
Risk of tuberculosis after initiation of antiretroviral therapy among people living with HIV in Europe - (11/17/22)
-
Treatment-Emergent Integrase Inhibitor Resistance Among Pediatric
and Adolescent Populations With HIV-1: A Systematic Review - (11/17/22)
-
Real-world Experience With the 2-Drug Regimen Dolutegravir and
Lamivudine in Women With HIV: A Systematic Literature Review - (11/17/22)
-
Initial plasma HIV-1 RNA and CD4+ T-cell count are determinants of virological outcomes with initial integrase inhibitor-based regimens: a prospective multinational RESPOND cohort consortium - (11/17/22)
- Risk Factors Associated With ≥ ±10% Weight Change in Treatment-Naïve and Treatment-Experienced People Living With HIV Initiating or Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies - (11/02/22)
- An Increase in Single-Tablet Regimen (STR) Utilization for People Living With HIV (PLWH) Enrolled in Medicaid Had Minimal Impact on Pharmacy Costs - (11/02/22)
-
ART Regimen Persistence Among Treatment-Experienced
Patients With HIV Switching to a MTR or STR Since 2018
- (11/02/22)
- Real-world Effectiveness And Tolerability Of Dolutegravir- Based Two-drug Regimens
- (11/02/22)
- Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials - (11/02/22)
-
Effectiveness of switching to DOR-based antiretroviral
therapy (ART) under real-world conditions in Germany - (11/02/22)
- New-onset Diabetes in Persons With HIV on BIC/FTC/TAF in Real-World Clinical Practice - (11/02/22)
-
Virologic Failure Rate 1.4% in 3 Years of CAB + RPV Phase 3 Trials:
Pre-existing RPV Resistance, CAB and RPV Troughs Predict Failure - Mark Mascolini (11/01/22)
- Single Infusion of VH3810109 bNAb Controls HIV at Two Doses - Mark Mascolini (11/01/22)
- Factors Associated With Weight Loss or Stable Weight After Continuing or Switching to a Doravirine-Based Regimen - (11/01/22)
- Metabolic and hepatic safety in ART experienced PLWH switching to a DOR-based regimen vs rilpivirine. Data from a real-life setting - (11/01/22)
- Long-term Efficacy and Resistance Analyses of D/C/F/TAF
in the Phase 3 AMBER and EMERALD Studies: Post 96-week Data - (11/01/22)
- Drug-Related Neuropsychiatric Adverse Events Across Phase 3/3b Studies of Long-Acting Cabotegravir + Rilpivirine Through Week 48 - (11/01/22)
- HIV-1 RNA Blips, Low-Level Viral Replication, and Mean CD4+/CD8+ Ratio During Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies Up to 152 Weeks of Therapy - (11/01/22)
-
Effects of the HIV-1 Maturation Inhibitor
GSK3640254 on QT Interval in Healthy Participants - (11/01/22)
-
Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study
- (11/01/22)
- Fostemsavir and QT Prolongation: Clinical Applications for Co-administration With Other Agents - (10/31/22)
-
A Multivariate Analysis of the Phase 3 BRIGHTE Trial, Through Week 24, to Identify Predictors of Virologic Response to Fostemsavir in Heavily Treatment-Experienced People Living With HIV - (10/31/22)
- Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in 5 randomised trials of 1074 pregnant women - (10/31/22)
- DTG Superior or Noninferior to PI/r After NNRTI Failure: Meta-Analysis of 4 Trials in Africa: VISEND, DAWNING, NADIA, 2SD - Mark Mascolini (10/31/22)
- Obesity Risk Higher With DTG Than Other Regimens
in 3 Big African Trials - ADVANCE, NAMSAL, VISEND - Mark Mascolini (10/31/22)
- DTG Better Than PI or EFV for Resuppression
of HIV After Apparent Virologic Failure in 4 African Trials - Mark Mascolini (10/31/22)
- UK Survey: Monkeypox Vax Highly Acceptable, but
Less Agreement on Public Health Measures - Mark Mascolini (10/31/22)
- Low COVID Mortality in HIV+ Europeans Similar to General Population- COVID Testing Tied to Younger Age, Female Gender, CVD and TDF - Mark Mascolini (10/31/22)
- Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2 infection in people with HIV: A cross-sectional study - Mark Mascolini (10/31/22)
- Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study - (10/31/22)
- Patient-Reported Outcomes After 152 Weeks of HIV Maintenance Therapy With Long-Acting Cabotegravir + Rilpivirine in the Phase 3b ATLAS-2M Study - (10/31/22)
-
Severity of Some Multimorbidity
Clusters on the Rise in People With HIV - Mark Mascolini (10/31/22)
- Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy for the Treatment of People Living With HIV With a Range of Comorbidities - (10/29/22)
- Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/28/22)
- Rapid ART Initiation Using B/FTF and TDF+3TC+EFV in HIV+ Patients in China - (10/28/22)
- Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure Over 152 Weeks - (10/28/22)
- 6-Month Outcomes of Every 2 Months Long-Acting Cabotegravir and Rilpivirine in a Real-World Setting - Effectiveness, Adherence to Injections, and Patient- Reported Outcomes of People Living With HIV in the German CARLOS Cohort - (10/28/22)
- Impact of switch to 3TC/dolutegravir on the intact and total HIV-1 viral reservoir in the Rumba Study - (10/28/22)
- Durable Efficacy of Switching From a 3-/4-Drug Tenofovir Alafenamide (TAF)-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine (DTG/3TC) in the TANGO Study Through Week 196 - (10/28/22)
- Total Lymphocyte and lymphocyte subset changes in participants receiving
islatravir (0.25, 0.75, and 2.25 QD) and doravirine (DOR) +/- lamivudine (3TC):
post-hoc analysis from a phase 2b dose-ranging study (P011) - (10/28/22)
- Modeling and Simulation to Optimize Islatravir Once Daily (QD) Doses in HIV Treatment Naive and Virologically Suppressed Populations - (10/28/22)
-
HIV Doubles Death Risk in National French Comparison With Matched Controls - Mark Mascolini (10/28/22)
- External validation of the Dat'AIDS score for predicting 5-year mortality among elderly people living with HIV in the Swiss HIV Cohort Study - (10/28/22)
- Common Adverse Events in Clinical Studies of People Using Lenacapavir for HIV Treatment - (10/28/22)
- Patient-Reported Symptom Outcomes Following DTG/3TC Use in
a Test-and-Treat Setting: Results From the STAT Study - (10/28/22)
- 2-Year Outcomes of Dolutegravir (DTG) and Lamivudine (3TC) in Art-Naive and Pre-treated People Living With HIV in Germany: Real-world Data From the German URBAN Cohort - (10/28/22)
- Age-Related Differences in Quality-of-Life Outcomes of People Living With HIV - (10/28/22)
- Outcomes After Switching From 144 Weeks of
Blinded DTG/ABC/3TC to 96 Weeks of Open-label B/F/TAF
- (10/28/22)
- Low Use of Preventive CVD Measures - Use of Preventive Measures
for Cardiovascular Disease in People Living with HIV
- (10/28/22)
- High Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Naive Adults With HIV-1 and High Baseline Viral Load (VL): 48-Week Subgroup Analyses of the GEMINI-1/-2 and STAT Trials - (10/28/22)
- Older people with well-controlled HIV have similar antibody and higher T-cell responses after vaccination against SARS-CoV-2 compared to demographically and lifestyle-comparable people without HIV
- Mark Mascolini (10/28/22)
- ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV - (10/28/22)
- Laboratory analysis of HIV infections in the year 1 unblinded period of HPTN 083: injectable cabotegravir for PrEP in MSM and TGW - (10/28/22)
- Patterns of Doravirine Use in a US Cohort - (10/27/22)
-
Real World Utilisation of Doravirine
Among People Living With HIV in England (DRIVE-REAL) - (10/27/22)
- Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study) - (10/27/22)
- Overcoming Barriers and Achieving Optimal Implementation of Cabotegravir and Rilpivirine
Long-Acting (CAB + RPV LA): Staff Study Participant (SSP) Results From the CAB + RPV
Implementation Study in European Locations (CARISEL)
- (10/27/22)
- Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Primary Results From the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/27/22)
-
ViiV HEALTHCARE PRESENTS POSITIVE DATA SHOWING VOCABRIA (CABOTEGRAVIR) AND REKAMBYS (RILPIVIRINE) CAN BE SUCCESSFULLY IMPLEMENTED ACROSS A RANGE OF EUROPEAN HEALTHCARE SETTINGS - (10/27/22)
- The Glasgow Manifesto International Coalition
of Older People with HIV (iCOPe HIV) - (10/26/22)
|
|
| |
|
|
|
|
|
|
